BeiGene
BGNE
#968
Rank
HK$155.82 B
Marketcap
HK$1,411
Share price
2.21%
Change (1 day)
2.80%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of September 2024 : HK$26.68 Billion

According to BeiGene 's latest financial reports the company has HK$26.68 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$HK$27.62 B-19.33%
2022-12-31$HK$34.24 B-28.38%
2021-12-31$HK$47.81 B59.42%
2020-12-31$HK$29.99 B293.66%
2019-12-31$HK$7.61 B-44.52%
2018-12-31$HK$13.73 B156.88%
2017-12-31$HK$5.34 B95.34%
2016-12-31$HK$2.73 B375.09%
2015-12-31$HK$0.57 B188.2%
2014-12-31$HK$0.19 B-166.56%
2013-12-31$-HK$0.31 Billion

Net assets for similar companies or competitors

Company Net assets differencediff. Country
HK$46.71 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$10.89 B-59.16%๐Ÿ‡บ๐Ÿ‡ธ USA